Bexarotene Prevents Premalignant Lesions in Mice
Author Information
Author(s): Li Y, Zhang Y, Hill J, Kim H-T, Shen Q, Bissonnette R P, Lamph W W, Brown P H
Primary Institution: Baylor College of Medicine
Hypothesis
Does bexarotene prevent cancer at early stages during mammary carcinogenesis?
Conclusion
Bexarotene significantly prevents the development of premalignant mammary lesions in MMTV-erbB2 mice.
Supporting Evidence
- Bexarotene treatment significantly reduced the number of hyperplasias in treated mice.
- Proliferation of mammary epithelial cells was significantly inhibited by bexarotene.
- Bexarotene did not induce apoptosis in mammary epithelial cells.
Takeaway
Bexarotene is a medicine that helps stop early signs of breast cancer in mice, making it less likely for them to get sick.
Methodology
MMTV-erbB2 mice were treated with bexarotene for 2 or 4 months, and the development of premalignant lesions was assessed.
Limitations
The study was conducted in a mouse model, which may not fully replicate human breast cancer.
Participant Demographics
Female MMTV-erbB2 transgenic mice
Statistical Information
P-Value
p=0.053 for some comparisons, p<0.01 for others
Statistical Significance
p<0.01
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website